Scroll Up
Scroll Down
Play Play Play Play
Holly Campbell
Is dit niet uw Personal Edition, klik dan hier
 
Neem contact met ons | Gratis wekelijkse updates | Tijdschriften | Registreer een collega
 
 
Prostaatkanker
 
   
 
ZOEKEN   
Doctor's Guide Free CME
Medline
Bijeenkomsten & Congressen
 

 VERKENNEN :
   Meest gelezen nieuws
 Al het nieuws  Al het nieuws
 Alle webuitzendingen / CME  Alle webuitzendingen / CME
 Alle casus  Alle casus
 Alle congressen  Alle congressen
 Alle medische bronnen  Alle medische bronnen
 Medical  Personal Edition



Waarschuwing | Privacy

 

 
 Recent nieuws - Prostaatkanker
    TopAbstracts in Prostate Cancer 02/03/2010 - (DGNews)
    TopAbstracts in Prostate Cancer 01/20/2010 - (DGNews)
    Race, Obesity Affect Outcomes Among Diabetics Following Prostatectomy - (DGNews)
    TopAbstracts in Prostate Cancer 01/06/2010 - (DGNews)
    Sexual Function Does Not Continuously Decline After Radiation Therapy for Prostate Cancer - (DGNews)

    Nieuwsarchief

     Recente webuitzendingen/CME - Prostaatkanker
    • Exploring the Link Between Hypogonadism and Metabolic Comorbidities
    • Diagnosing Hypogonadism: Recommendations for Testing and Treating to Improve Outcomes
    • Primary Care Update in Urology
      Prostate Cancer: Recent Developments Relevant for Internal Medicine Physicians
      Emerging Research May Improve Prostate Cancer Treatment

      Archief van webuitzendingen/CME

       Recente casus - Prostaatkanker
        Coexistence Of Pernicious Anemia And Prostate Cancer - 'An Experiment Of Nature' Involving Vitamin B12 Modulation Of Prostate Cancer Growth And Metabolism: A Case Report
        Incidental Carcinoma of the Prostate Gland Presenting with Initial Manifestation of Disseminated Intravascular Coagulopathy (Dic) in a Middle Aged Man: A Case Report
        Non-Prostatic Pathology on Prostate Needle-Biopsy - Colorectal Carcinoid: A Case Report
        A 70-Year-Old Male Having Advanced Prostate Cancer Presenting with Hypercalcemia and Diffuse Osteoblastic Bone Metastases: A Case Report
        A Dramatic, Objective Antiandrogen Withdrawal Response: Case Report and Review of the Literature

        Archief van casus
          




        personal edition > prostaatkanker > nieuws
        divider

          Stuur deze DGDispatch per e-mail naar een collega

        DGDispatch


        Postoperative Nightly Sildenafil (Viagra) Promotes Erectile Function Post-prostatectomy: Presented at AUA

        By Paula Moyer

        CHICAGO, IL -- May 1, 2003 -- Nightly use of sildenafil (Viagra) after nerve-sparing radical retropubic prostatectomy (NSRRP) appears to help promote the return of normal spontaneous erectile function.

        "Nightly use of sildenafil after prostatectomy is the bridge between two key issues in men's urogenital health -- erectile dysfunction and prostate cancer," said Harin Padma-Nathan, MD, a clinical professor of urology, Keck School of Medicine, University of Southern California in Los Angeles. He is also in private practice in Beverly Hills.

        Dr. Padma-Nathan presented the findings here April 29th at the 98th Annual Meeting of the American Urological Association.

        The findings show that nightly administration of sildenafil for 9 months after NSRRP increased the return of spontaneous erections seven-fold compared with placebo, and that treatment was well tolerated, he said.

        He noted that NSRRP has better potency outcomes over radical prostatectomy.

        "However, even in experienced surgical hands, a large number of patients don't return to normal erectile function," Dr. Padma-Nathan said. "The majority [of patients] are highly potent before their surgical procedure, and therefore, what they want is not the same as a man who is being treated for erectile dysfunction."

        He said that one hypothesis is that, during surgery, the nerves to the penis are traumatized. Even though the nerves do recover, long-term ED could occur due to muscle atrophy during convalescence as the result of neuropraxia and hypoxia.

        Conversely, he said, nightly sildenafil may promote oxygenation. Therefore, the investigators wanted to see if nightly treatment with sildenafil would facilitate the return to normal erectile function.

        The rationale was that early postoperative intervention with intracavernosal alprostadil was shown to promote post-NSRRP erections. Other research has shown that nightly sildenafil improves nocturnal erections. Therefore, Dr. Padma-Nathan and his colleagues wanted to see whether nightly sildenafil would promote the return of normal erections after bilateral NSRRP.

        The investigators followed 76 men with prostate cancer who were to undergo NSRRP. They all had normal preoperative erectile function, which the investigators defined as a combined score of at least 8 for questions 3 and 4 from the International Index of Erectile Function (IIEF) questionnaire, and as a normal erectile function as measured by nocturnal penile tumescence testing. Normal tumescence was defined as at least 10 continuous minutes of erection with at least 55% base rigidity.

        Four weeks after NSRRP the patients were randomized to 1 of 3 nightly treatment groups: 23 received 50 mg of sildenafil; 28 received 100 mg of sildenafil, and 25 received a placebo. The men were treated for 36 weeks in a double-blind fashion.

        The investigators assessed their erectile function 8 weeks after they discontinued treatment by asking the question, "Over the past 4 weeks, have your erections been good enough for satisfactory sexual activity?"

        The investigators also administered the IIEF questionnaire, and patients' erections were assessed with nocturnal penile tumescence measurement. The investigators defined responders as those who had a combined score of at least 8 for questions 3 and 4 on the IIEF and a positive response to the sexual activity question.

        At the time of this assessment, 48 weeks after bilateral NSRRP, 27% of the 51 patients receiving sildenafil demonstrated a return of spontaneous erectile function. Among the 25 placebo patients, 4% had a similar response (P=0.0156). The postoperative nocturnal penile tumescence assessments were consistent with this finding, Dr. Padma-Nathan said.

        The patients reported no treatment-related serious adverse events, although 2 patients discontinued due to treatment-related adverse events.

        These results support using nightly sildenafil as a postoperative treatment regimen for these patients, Dr. Padma-Nathan concluded.


        [Study title: Postoperative Nightly Administration of Sildenafil Citrate Significantly Improves the Return of Normal Spontaneous Erectile Function After Bilateral Nerve-Sparing Radical Prostatectomy. Abstract 1402]



        Stuur deze DGDispatch per e-mail naar een collega   Om af te drukken, gebruikt u deze versie






        Alle inhoud Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. Alle rechten voorbehouden.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send